

Marine Biodiscovery: Overview, hurdles and bottlenecks

Marcel Jaspars Marine Biodiscovery Centre University of Aberdeen Scotland, UK m.jaspars@abdn.ac.uk Offers advantage over comparable terrestrial resource: Superior performance Better economics

Unprecedented activity in particular application: Enzymes: new reactivity/new biotransformation Small molecules: new mechanism of action Materials: new properties



Marine Natural Products on the Market



Vent Polymerase Origin: Vent bacterium Production: Recombinant



Prialt for pain Origin: Phillippino cone snail Production: Recombinant



ω-3 polyunsaturated fatty acids
 for heart disease Source: Fish
 Production: Fish



Halaven for cancer Origin: Japanese deep water sponge Production: Chemical synthesis PHARMASEA

IBiodiscovery is the

discovery of compounds and associated ideas from natural sources to develop novel biomedicines.

IBiodiscovery generates chemical diversity that is used to find initial biological activity in disease focused screens

IBiodiscovery also includes the development of biomedical research tools, antifoulants, catalysts, nutraceuticals and cosmeceuticals.



PHARMASEA *

4





Access - Legal

Create Science/Policy Interface



Access - Physical







Bottlenecks

- High daily rate
- Limited number of vessels globally
- Access competitive
- Long time between bid for time and actual cruise
- Many different types of science accommodated may lead to compromises
- Data capture & storage

Possible Solutions

- Shared resources and bartering systems
- Sharing of samples
- Biobanks
- Cheaper sampling technology
- Systems to encourage data deposition







Quality of Marine Bioresources – Habitat Selection





Cold Oceans



Deep Oceans



Thermal Vents



Quality of Marine Bioresources – Strain Isolation & ID



0.01

Selective Isolation Methods Target particular taxa

Taxonomic Identification

Polyphasic taxonomy: Morphology DNA-based Chemotaxonomy



Genomics/Bioinformatics

- Is genome and metagenome information sufficient?
 - Many genes found in marine species are not in the current bioinformatic databases
 - The function of many of these genes cannot be determined without laboratory work
- Impact of CBD/Nagoya
 - Who acquired/deposited the data and with what authority?
 - Who has access to the data?



PHARMA





Biomass









Elicitation/Stress and Molecular Tools



What stresses/media to use?



Difficulty in cloning genes of marine origin due to lack of suitable tools (vectors/hosts)







Dereplication and Data Management







Purification & Assays







Extract library



Whole animal



Cell based



Enzyme based



Assay Considerations

- Assay validation
- Throughput vs information content
- Artefacts (false positives/negatives)
- Pan-interferences
- Counterscreens/secondary assays
- Data management
- Decision protocol for follow-up studies









Novelty/Structure Determination

Better chemical informatics

- Find known compounds & reduces wasted effort
- Discover known families
- Pinpoints new compounds
- Automated processing of large volume of data

Rapid Structure Elucidation

- State-of-the-art equipment
- Computer aided methods
- Data management



Use of open source databases

Automated structure determination workflow



Mechanisms to transfer marine biotechnology to end users whilst acknowledging:

Current bottlenecks in marine biodiscovery pipeline

Need for legal certainty over marine biodiversity collection (CBD/NP & UNCLOS).

Regulatory stress on companies (EMEA/EFSA).

Lack of risk taking by companies due to shareholder pressure.

Possible actions

Address technical challenges in pipeline

Provide information/organise meetings to raise awareness of opportunities

Work with regulators and practitioners to develop appropriate framework



People, Facilities and Projects

Problem

- Lack of expertise in marine biotechnology (microbiology/ genetics/chemistry/assays etc)
- Lack of interdisciplinary training capacity.
- Few integrated facilities covering the whole pipeline
- Decentralisation of current projects
 More management
 Slower sample transfer
 Decision protocols slower

Possible Solution

- Build networks and consortia to introduce scientists from other disciplines
- Develop integrated MSc/PhD programmes (eg ITN)
- Build marine biotechnology centres

- Simplify management processes
- Allow more autonomy
- Better communication



Overarching Problems

Problem

• Large scale production of materials

 Long term maintenance of data Genomic Assay Compound

Possible Solution

Better cultivation facilities Better molecular tools

Bioinformatic databases Assay databases/LIMS/OPENSCREEN Open source databases/ChemSpider

 Long term maintenance of material Strains Extracts Compounds

Biobanks Central screening facility/OPENSCREEN Central compound repository (*cf* Open Source Drug Discovery in India)



Project Lifetimes

- Limited lifetime projects come to a sudden end jeopardising
 - Continuity promising compounds will not be pursued
 - Maintenance and use of data acquired
 - Maintenance and use of materials generated
 - Fragmentation of highly functioning teams
- Consider continuing support for successful projects (grant renewal)
 - Must be competitive and based on previous results and track record
 - Do this without disadvantaging new projects (eg by including new partners in renewals)
 - Ensure maintenance of data and materials







"The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013 under grant agreement n° 312184)"